Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-presents-long-term-data-on-treatment-with-velmanase-alfa-in-alpha-mannosidosis-and-announces-additional-presentations-at-the-20th-annual-worldsymposium-research-meeting-302058140.html
https://www.prnewswire.com/news-releases/chiesi-group-and-oak-hill-bio-announce-license-and-development-agreement-to-develop-manufacture-and-commercialise-ohb-607-a-potentially-transformative-neonatal-therapy-302028868.html
https://www.fiercepharma.com/marketing/chiesi-buffing-environmental-credentials-works-bbc-spread-message-about-greener-inhalers
https://www.prnewswire.com/news-releases/chiesi-group-signed-a-license-agreement-with-haisco-pharmaceutical-to-develop-manufacture-and-commercialise-a-novel-reversible-dipeptidyl-peptidase-1-inhibitor-for-bronchiectasis-301992400.html
https://www.pmlive.com/pharma_news/nice_recommends_chiesis_elfabrio_for_adults_with_fabry_disease_1497865
https://www.globenewswire.com/news-release/2023/07/31/2714543/0/en/Santhera-Completes-Divestment-of-Raxone-Idebenone-Business-to-Chiesi-Group.html
https://www.contractpharma.com/contents/view_breaking-news/2023-07-19/kindeva-drug-delivery-chiesi-group-and-ht-presspart-team-up/?widget=listSection
https://endpts.com/chiesi-protalixs-fabry-disease-treatment-is-approved-as-elfabrio-joins-fabrazyme-galafold/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761161